Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Saved in:
| Title: | Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. |
|---|---|
| Authors: | Rosenstock J; Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, TX, USA. Electronic address: juliorosenstock@dallasdiabetes.com., Yabe D; Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan; Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan; Center for One Medicine Innovative Translational Research, Gifu University Institute for Advanced Studies, Gifu, Japan., Cox D; Eli Lilly and Company, Indianapolis, IN, USA., Li J; Eli Lilly and Company, Indianapolis, IN, USA., Denning M; Eli Lilly and Company, Indianapolis, IN, USA., Wu WS; Eli Lilly and Company, Indianapolis, IN, USA., Liu R; Eli Lilly and Company, Indianapolis, IN, USA., Zhao Y; Eli Lilly and Company, Indianapolis, IN, USA. |
| Corporate Authors: | ACHIEVE-3 Investigators |
| Source: | Lancet (London, England) [Lancet] 2026 Mar 21; Vol. 407 (10534), pp. 1147-1160. Date of Electronic Publication: 2026 Feb 26. |
| Publication Type: | Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial; Comparative Study; Equivalence Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1474-547X |
|---|---|
| DOI: | 10.1016/S0140-6736(26)00202-3 |
